| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C26H31ClFN5O4S |
| Molar mass | 564.07 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADSB-FUB-187 is anindazole-basedsynthetic cannabinoid. It is a potentagonist of theCB1 receptor with abinding affinity ofKi = 0.09 nM and anEC50 of 1.09 nM.[1] It was originally developed byPfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms ofKi, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.[2]
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-marketsynthetic cannabis products.[3]
Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |